halofuginone has been researched along with Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagler, A; Pines, M | 1 |
| Bona, C; McGaha, TL; Phelps, RG; Spiera, H | 1 |
2 other study(ies) available for halofuginone and Sclerosis
| Article | Year |
|---|---|
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Topics: Administration, Topical; Adult; Animals; Collagen; Gene Expression; Graft vs Host Disease; Humans; Male; Neck; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Rabbits; Range of Motion, Articular; Sclerosis; Skin; Skin Transplantation | 1999 |
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
Topics: Animals; Cells, Cultured; Collagen; Collagen Type I; DNA-Binding Proteins; Fibroblasts; Gene Expression; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Mutant Strains; Piperidines; Quinazolines; Quinazolinones; Receptors, Transforming Growth Factor beta; Sclerosis; Signal Transduction; Skin; Skin Diseases; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2002 |